Ticker Symbol: MIRM
Mirum Pharmaceuticals Inc
$15.89 - 20-11-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001759425
Company Profile
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. Mirum has submitted an NDA for maralixibat in the treatment of cholestatic pruritus in patients with ALGS. Additionally, Mirum's marketing authorization application for the treatment of pediatric patients with PFIC2 has been accepted for review (validated) by the European Medicines Agency.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: mirumpharma.com
CEO: N/A
Tags:
- Health Technology
- Pharmaceuticals: Major
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $29.77
Change:
$0.47
(
1.60%)
Days Range: $29.09 - $30.08
Beta: 0.86
52wk. High: $33.39
52wk. Low: $17.48
Ytd. Change 51.86%
50 Day Moving Average: $29.91
200 Day Moving Average: $27.22
Shares Outstanding: 38297975
Valuation
Market Cap: 114.0B
PE Ratio: -6.25
EPS (TTM): -4.76
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A